AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for AEZS
0.0880
+0.0025 (2.92%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.09 - 0.10
52 week 0.08 - 1.54
Open 0.09
Vol / Avg. 15.57M/9.10M
Mkt cap 15.19M
P/E     -
Div/yield     -
EPS -0.41
Shares 182.29M
Beta 2.30
Inst. own 10%
Nov 2, 2015
Q3 2015 AEterna Zentaris Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
AEterna Zentaris Inc at Rodman & Renshaw Global Investment Conference - 5:05PM EDT - Add to calendar
Aug 14, 2015
Q2 2015 AEterna Zentaris Inc Earnings Call
Aug 12, 2015
AEterna Zentaris Inc at Canaccord Genuity Growth Conference
Aug 12, 2015
Q2 2015 AEterna Zentaris Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -7689.34% -156245.50%
Operating margin -4055.33% -339954.50%
EBITD margin - -309345.50%
Return on average assets -99.18% -32.24%
Return on average equity -407.94% -108.96%
Employees 88 -
CDP Score - -

Address

1405 du Parc-Technologique Blvd
QUEBEC, QC G1P 4P5
Canada
+1-418-6528525 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aeterna Zentaris Inc. is a Canada based biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company currently has three wholly owned direct and indirect subsidiaries, Aeterna Zentaris GmbH (AEZS Germany), Zentaris IVF GmbH, a wholly owned subsidiary of AEZS Germany, and Aeterna Zentaris, Inc. The Company’s product candidates include Macrilen (macimorelin), an orphan drug that evaluates growth hormone deficiency in adults, and zoptarelin doxorubicin, a targeted therapy for endometrial cancer and other cancers.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Philip A. Theodore Senior Vice President, Chief Administrative Officer, General Counsel
Age: 61
Bio & Compensation  - Reuters
Richard Sachse M.D., Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Keith Santorelli Vice President - Finance
Bio & Compensation  - Reuters
Michael Teifel Vice President - Non-Clinical Sciences
Bio & Compensation  - Reuters
Juergen H. L. Ernst Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
M. Marcel Aubut QC Independent Director
Bio & Compensation  - Reuters
Jose P. Dorais Independent Director
Bio & Compensation  - Reuters